Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome.
Twenty-three patients with polycystic ovary syndrome and anovulatory infertility have been treated with bromocriptine. All had previously failed to respond to clomiphene. Twenty had normal serum prolactin concentrations and, of these, four (20%) developed regular ovulatory cycles. All three women with moderate hyperprolactinaemia ovulated regularly on bromocriptine so that, overall, seven of 23(30%) responded, which was a significantly higher proportion than that observed during a control period of no treatment. A further eight women ovulated at least once during the study period but these occasional ovulations were no more common during bromocriptine than with either clomiphene or no treatment. No suppression of LH was noted except during the luteal phase of ovulatory cycles and there was no change in the pattern of pulsatile release of LH. Testosterone and androstenedione concentrations remained elevated and unchanged. We conclude that bromocriptine may be expected to induce ovulation in hyperprolactinaemic women with polycystic ovary syndrome but that there is no clear indication for its use in clomiphene-resistant patients with normal serum prolactin concentrations.
D000328:Adult; D000735:Androstenedione / Q000097:blood; D001971:Bromocriptine / Q000627:therapeutic use*; D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D002996:Clomiphene; D001971:Bromocriptine; D013739:Testosterone; D000735:Androstenedione; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone